Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 129   

Articles published

VRX 130.26 +1.27 (0.98%)
price chart
Valeant Pharmaceuticals International Inc names top shareholder ValueAct's ...
Valeant Pharmaceuticals International Inc said on Thursday it had named the head of a top shareholder, ValueAct Capital, to its board of directors and vowed to continue with its hostile takeover attempt on Botox maker Allergan Inc. ValueAct had a seat ...
Valeant Pharmaceuticals Intl Inc (VRX): ValueAct Capital Raises Stake as ...  Insider Monkey (blog)
Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant ...  MarketWatch
Related articles »  
2 Reasons to Avoid Valeant Pharmaceuticals Intl Inc, and 1 Stock to Buy Instead
In Canada, few companies are able to seriously compete on the global stage. But Valeant Pharmaceuticals Intl Inc (TSX: VRX)(NYSE: VRX) is one of them, and has become one of the country's big success stories.
3 Reasons to Buy Valeant Pharmaceuticals Intl Inc.
Valeant Pharmaceuticals Intl Inc (TSX:VRX)(NYSE:VRX) is Canada's largest pharmaceutical company. No other pharmaceutical company in Canada comes close.
3 Reasons to Choose Brookfield Asset Management Inc. Over Valeant ...
Brookfield Asset Management (TSX: BAM.A)(NYSE: BAM) and Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX) are two of Canada's most successful companies.
Related articles »  
Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan ...
LAVAL, Quebec, Sept. 24, 2014 /PRNewswire/ -- J. Michael Pearson, Chairman and Chief Executive Officer of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today sent a letter to Allergan, Inc.'s (NYSE: AGN) CEO David Pyott and Lead ...
Pharma Stock News: Valeant Pharmaceuticals International Intl Inc (NYSE:VRX ...  Equities Focus (registration)
Allergan close to deal with Salix to fend off hostile takeover: report  Financial Post
Related articles »  
Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub ...
26, 2014 /PRNewswire/ -- Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically ...
Bausch + Lomb Receives Successful Results from Phase 3 Study  Drug Discovery & Development
Bausch + Lomb's Phase 3 Sub-Micron Ophthalmic Gel Trial Meets Primary ...  NASDAQ
Related articles »  
Doubts mount about Valeant Pharmaceuticals' tax structures
MONTREAL - The disclosure by Valeant Pharmaceuticals International Inc. that it is under audit by the U.S. Internal Revenue Service is raising further doubts among tax specialists about the future of the Quebec-based drug company's tax strategies ...
Related articles »  
Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO� (latanoprostene ...
LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Sept. 25, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (NYSE Euronext Paris: COX) today ...
Scanning Pharma Equities - Novo Nordisk, Teva Pharma Industries, Sanofi ...
On Thursday, shares in Valeant Pharmaceuticals International Inc. recorded a trading volume of 5.61 million shares, higher than its three months average volume of 2.51 million shares.
Related articles »  
CORRECTED-Valeant Pharmaceuticals' third-quarter sales to rise -filing
(Corrects source of filing to Allergan, not Valeant. Adds Valeant statement from last week). Sept 29 (Reuters) - Valeant Pharmaceuticals International Inc's sales are expected to rise 15 percent in the third quarter but will face a tougher fourth ...
Valeant Pharma pushes potential of eye treatment, company focus on research  Times Colonist
Allergan Board of Directors Issues Statement  MarketWatch
Related articles »